Literature DB >> 7178653

High pressure liquid chromatographic determination of cyclosporin-A in human plasma.

B Leyland-Jones, A Clark, W Kreis, R Dinsmore, R O'Reilly, C W Young.   

Abstract

Periodic monitoring of plasma drug concentrations has been suggested as a means whereby the toxicity of Cyclosporin A (CyA) can be reduced in patients undergoing bone marrow transplantation. We have developed a sensitive and specific method for the determination of CyA in plasma using reverse phase high pressure liquid chromatography (HPLC). Cyclosporin D was used as the internal standard. The lower limits of detection are 100 ng/ml in biological fluids and 20 ng per injection onto the column. We have analyzed plasma samples from patients who received CyA at doses which ranged from 8 to 15 mg/kg/day. Although all patients experienced toxic or therapeutic effects, plasma concentrations of CyA were consistently less than 100 ng/ml when analyzed by this method. We conclude that analytical methods currently available for the detection of CyA are unsuitable for the monitoring of patients who receive this agent.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7178653

Source DB:  PubMed          Journal:  Res Commun Chem Pathol Pharmacol        ISSN: 0034-5164


  3 in total

1.  Cyclosporine pharmacokinetic profiles in liver, heart, and kidney transplant patients as determined by high-performance liquid chromatography.

Authors:  G J Burckart; R Venkataramanan; R J Ptachcinski; T E Starzl; B P Griffith; T R Hakala; J T Rosenthal; R L Hardesty; S Iwatsuki; J Brady
Journal:  Transplant Proc       Date:  1986-12       Impact factor: 1.066

Review 2.  Clinical pharmacokinetics of cyclosporin.

Authors:  R J Ptachcinski; R Venkataramanan; G J Burckart
Journal:  Clin Pharmacokinet       Date:  1986 Mar-Apr       Impact factor: 6.447

3.  Cyclosporin: pharmacokinetics and detailed studies of plasma and erythrocyte binding during intravenous and oral administration.

Authors:  B Legg; S K Gupta; M Rowland; R W Johnson; L R Solomon
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.